OKYO Pharma ADR (NASDAQ:OKYO) is a biopharmaceutical company focused on developing innovative treatments to combat eye diseases, particularly those causing significant discomfort and vision impairment. Its pipeline of projects revolves around novel therapeutic peptides and small molecules aimed at addressing unmet needs in ophthalmology, with a keen emphasis on dry eye disease and chronic pain in ocular surfaces. OKYO Pharma's objective is to advance these cutting-edge therapies from the research stage through clinical trials, with the aim of eventually bringing new solutions to patients suffering from these debilitating conditions. The company is dedicated to improving quality of life through scientific breakthroughs and rigorous testing of their potential medications.